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Background: Markers of kidney dysfunction and damage have potential to detect chronic kid-
ney disease (CKD) in early stages. However, data on long-term variation of these markers in
healthy dogs is lacking and is crucial for the interpretation of results.
Hypothesis/Objectives: To determine temporal variations of serum cystatin C (sCysC) and uri-
nary retinol-binding protein (uRBP), neutrophil gelatinase-associated lipocalin (uNGAL), immuno-
globulin G (uIgG), and C-reactive protein (uCRP) in healthy dogs.
Animals: Eight clinically healthy adult Beagles were evaluated.
Methods: Longitudinal observational study. Serum cystatin C was determined by particle-
enhanced nephelometric immunoassay. Urinary retinol-binding protein, uNGAL, uIgG and uCRP
were determined by ELISA and concentrations were indexed to urinary creatinine. Within- and
between-dog variance components (VC) and within-dog coefficients of variation (CV) were
determined from blood and urine collected at eight time points over 1.5 years.
Results: Urinary C-reactive protein (uCRP) concentrations were consistently below the detec-
tion limit (5.28 ng/mL). Mean  within-dog standard deviation for sCysC, uRBP/c, uNGAL/c
and uIgG/c was 0.15  0.01 mg/L, 0.09  0.03 mg/g, 2.32  2.03 μg/g and 12.47  10.98
mg/g, respectively. Within-dog CV for sCysC, uRBP/c, uNGAL/c and uIgG/c was 8.1%, 33.7%,
87.2% and 88.1%, respectively.
Conclusions and clinical importance: Serum cystatin C, uRBP/c, uNGAL/c and uIgG/c exhibit a
wide range of long-term within-dog variability. Researchers and veterinarians might need to
take this into account when interpreting their results. To assess their diagnostic and predictive
ability, future studies need to establish reference ranges for healthy dogs and dogs with CKD.
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1 | INTRODUCTION
Kidneys have a great compensatory ability when affected by insults
that could compromise their function.1 As a consequence, conventional
markers of renal disease, such as serum creatinine, often lead to late
diagnosis of chronic kidney disease (CKD).2 This makes it difficult and
challenging for veterinarians to detect kidney disease at an early stage
when proper treatment might slow CKD progression and improve lon-
gevity and quality of life.3 Furthermore, while measurement of
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glomerular filtration rate (GFR) is the gold standard to determine kidney
function, the clinical application in veterinary medicine is cumbersome
as multiple sampling is often required and filtration markers or special-
ized equipment to analyze the markers are not commercially available.4
Therefore, there is a search for more sensitive markers of kidney dis-
ease and indirect markers of GFR in veterinary medicine.
Combined use of sensitive indirect markers of GFR and site-
specific (i.e., glomerular and tubular) markers of renal disease, allowing
for earlier detection of CKD, could potentially offer veterinarians a
powerful alternative, particularly in the context of routine screening
or serial monitoring of individuals. Serum symmetric dimethylarginine
is a more sensitive and specific indirect GFR marker when compared
to creatinine.5,6 However, there are other markers that have potential
to detect early renal dysfunction. Serum cystatin C (sCysC), for exam-
ple, is a low molecular weight (MW) protein that meets many of the
requirements for an ideal endogenous GFR marker.7 Serum cystatin C
is a better marker of GFR than serum creatinine and has good diag-
nostic accuracy in predicting CKD in humans.8,9 In dogs, sCysC has a
comparable or better sensitivity to detect a decrease in GFR com-
pared to serum creatinine.7 However, it lacks specificity.7 To our
knowledge, there are no studies yet comparing sCysC directly to
serum symmetric dimethylarginine in dogs.
Several site-specific urinary markers have also been investigated
in recent years. C-reactive protein (CRP) and immunoglobulin G (IgG)
are both high MW proteins associated with glomerular damage when
detected in urine.10 Retinol-binding protein (RBP) and neutrophil
gelatinase-associated lipocalin (NGAL) are both low MW proteins that
reflect tubular damage.10 These markers increase in dogs with CKD
and some correlate to glomerular lesions, tubulointerstitial lesions, or
both of differing magnitudes.10–13
Despite the potential of these markers, their use is still limited to
research purposes. Generally accepted reference ranges and cut-off
values do not exist yet due to lack of standardized methods of analysis
and large-scale studies. Moreover, information on long-term variation
of both healthy and diseased dogs is lacking for sCysC and urinary
(u) RBP, NGAL, IgG and CRP. Knowing the stability or variability of
each marker’s concentration in function of time is needed to deter-
mine how it should be interpreted when compared to established ref-
erence ranges. Therefore, the aim of this study was to determine the
temporal variation of markers of kidney disease sCysC, uRBP, uNGAL,
uIgG and uCRP in healthy dogs during a period of 1.5 years.
2 | MATERIALS AND METHODS
This longitudinal study of 1.5 years was approved by the Local Animal
Ethics Committee (Faculties of Veterinary Medicine and Bioscience
Engineering, Ghent University, Belgium) and performed in accordance
with European and national regulations for the care and use of animals
(EC2015/92).
2.1 | Animals
Eight healthy lean adult Beagles (three intact and one spayed female,
two intact and two neutered males) were included in the study. Dogs
were considered healthy if no clinically relevant abnormalities were
found on their medical history, physical examination, complete blood
count, serum biochemistry (serum creatinine < 1.4 mg/dL based on
International Renal Interest Society guidelines for staging CKD),
abdominal ultrasonography, and urinalysis on urine collected by
ultrasound-guided cystocentesis (urine sediment, dipstick test, specific
gravity (USG), including protein-to-creatinine ratio (UPC), and bacterial
culture). At the start of the study dogs were between 2.7 and 8.3 years
(mean  standard deviation, 4.7  1.7 years) and had an ideal body
weight (BW) (11.58  1.64 kg) and an ideal body condition score
(BCS) of four based on a 9-point scale.14
2.2 | Procedures
After adapting to the study’s diet for four weeks, measurements were
made at week 0, 12, 24, 36, 47, 56, 68 and 83 of the study. All dogs
received the same dry commercial adult maintenance diet
(Veterinary™ HPM Adult Large and Medium, Virbac, Carros, France)
during the entire study. The amount was adjusted weekly to maintain
an ideal BW and BCS (4 - 5/9), both of which were assessed weekly.
Water was provided ad libitum. Blood and urine samples were col-
lected at the eight time points. Dogs were fasted for at least 12 hours
prior to samples collections. Blood samples (5 mL) were collected from
the jugular vein (21G needle). Complete blood count and serum bio-
chemistry were repeated at weeks 24, 47, 56 and 83.15 Serum was
acquired by centrifuging blood collected in a serum tube within two
hours of collection for 5 minutes at 2000 × g at 21C. Serum was
stored at -80C in aliquots of 300 μL until analysis. Urinalysis (dipstick
analysis, USG, UPC, sediment analysis, and bacterial culture) were per-
formed on an aliquot of morning urine (5 mL) collected by ultrasound-
guided cystocentesis (22G needle) at all eight time points.15 An aliquot
of 5 mL urine was centrifuged for 3 minutes at 447 × g within
30 minutes of collection. The supernatant was aliquoted (200 μL) and
stored at -80C until analysis.
2.3 | Assays
Serum cystatin C was measured with particle-enhanced nephelomet-
ric immunoassay (PENIA) previously validated for dogs.15,16 Samples
for sCysC were analyzed in four batches. The limit of detection (LOD)
of PENIA for sCysC was 0.05 mg/L. uRBP concentrations were ana-
lyzed with a commercially available human ELISA kit (Immunology
Consultants Laboratory, Portland, OR, USA). uNGAL (BioPorto Diag-
nostics, Hellerup, Denmark), uIgG (Immunology Consultants Labora-
tory, Portland, OR, USA) and uCRP (Immunology Consultants
Laboratory, Portland, OR, USA) concentrations were determined with
commercial canine-specific ELISA kits. uRBP, uNGAL, uIgG and uCRP
assays were previously validated for use with canine urine.12,17 All
immunoassays were performed in two batches and were used accord-
ing to manufacturer’s instructions and performed as previously
described.12,17–19 The LOD and limit of quantification (LOQ) were
determined in previous studies.17,19 The LOD and LOQ of the uRBP,
uNGAL, uIgG and uCRP assays were 14.11 ng/mL and 18.93 ng/mL,
5.35 pg/mL and 9.60 pg/mL, 19.69 ng/mL and 29.72 ng/mL and 5.28
ng/mL and 7.76 ng/mL, respectively. The concentration of each
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urinary marker was expressed as a ratio to urinary creatinine (/c) to
account for variations in urine concentration.18 Urinary creatinine was
determined by the modified kinetic Jaffé method.17
2.4 | Statistical Analysis
Statistical analysis was performed with R (version 3.3.2; Rstudio ver-
sion 1.0.143). For the immunoassays, if the obtained concentrations
of samples that were minimally diluted (1:2) were below the LOD or
between the LOD and LOQ, the median between 0 and LOD or the
median between LOD and LOQ were used as a value for statistics,
respectively. When samples were not minimally diluted, a missing
value was assigned for concentrations that fell below the LOD or
between the LOD and LOQ. A random effects model using restricted
maximum likelihood (lme4 package) was used to estimate the variance
components (VC).20 Two VCs were estimated: v1 representing the
variation between repeated measurements on the dog and v2 repre-
sents the extra variation when considering observations of different
dogs. The VCs were used to determine 95% reference intervals for
repeated observations in the same dog and for repeated observations
in different dogs. The coefficient of variation (CV), defined as the ratio
of the standard deviation over the mean, was determined for the
within-dog repeated observations.
3 | RESULTS
During the study, percentage BW changes varied between -3.9% and
14.8% compared to week 0. BCS, however, remained within the ideal
range (BCS 4 – 5/9), as each unit increase is associated with a 10-15%
change in weight on a 9-point scale.21 One of the dogs had persistent
mild proteinuria (UPC 0.62  0.14) without azotemia from week 12.
In another dog euthanized after week 56 because of multicentric lym-
phoma, only the first 6 of the 8 time points were included for statisti-
cal analysis. All dogs had a serum creatinine concentrations less than
1.4 mg/dL (0.62  0.07 mg/dl), USG of 1.038 (median; range,
1.008-1.052), negative urine bacterial culture and unremarkable uri-
nalysis except for microscopic hematuria (> 27 red blood cells/μL
urine) in some of the samples. Microscopic hematuria was present in
one sample at week 0, seven samples at week 24, one sample at week
36, two samples at week 47, and four samples at week 56. uCRP con-
sistently had concentrations below the LOD of the assay, and was
therefore not included in the statistical analysis.
Table 1 summarizes the estimated VCs for sCysC, uRBP/c, uIgG/c
and uNGAL/c. Variation from repeated measurements on the same
dog over 1.5 years was smaller than variation from measurements
made on different dogs for sCysC, uIgG/c and uRBP/c. Of all markers
examined, sCysC had the lowest within-dog CV (8.1%), followed by
uRBP/c (33.7%), while uIgG/c and uNGAL/c had the highest within-
dog CVs (88.1% and 87.2%, respectively) (Table 2).
4 | DISCUSSION
This longitudinal study investigates markers of kidney disease in dogs
over a period of 1.5 years to determine both within- and between-
dog variability for each marker in a highly controlled group of dogs,
i.e., same breed, kept under the same conditions and fed the same
diet. Moreover, the study and sample analyses were performed in a
standardized manner to reduce further variation. Except for uNGAL/c,
the variation arising from repeated measurements within the same
dog was smaller than the variation from measurements made in differ-
ent dogs for sCysC, uRBP/c and uIgG/c. Among all markers studied,
sCysC had the smallest within-dog CV, suggesting that the change in
concentrations obtained from serial measurements in healthy dogs is
limited. In addition, low intra-individual variability allows the dog to be
its own reference in the detection of early changes in concentration
after serial measurements (i.e., trending), as in the case of serum creat-
inine.10 Compared to sCysC, uRBP/c, uNGAL/c and uIgG/c exhibit a
high degree of within-dog variability. This means that the obtained
values from sequential samples from one healthy dog can differ sub-
stantially. As such, interpretation of a single sample for these markers
should be done with caution, particularly if there is overlap between
the concentration of healthy dogs and dogs with CKD.
The biological variance of sCysC was investigated a decade ago in
healthy dogs.22 Even with a longer study duration in the current study
(83 weeks vs. 24 weeks); a longer time interval between measure-
ments (median 12 weeks vs. 2 weeks); the use of a single breed
instead of two; and the use of PENIA instead of particle-enhanced
turbidimetric immunoassay to analyze sCysC, within-dog variability of
sCysC appears to be quite low in dogs (8.1% vs. 12.3%). Currently,
there is still no standardized method of analyzing sCysC and no
canine-specific assay available. Therefore, it remains difficult to
TABLE 1 Estimated variance components, v1 for variation from
repeated measurements on the same dog and v2 for extra variation
from measurements from different dogs, of sCysC, uRBP/c, uNGAL/c
and uIgG/c in healthy beagles (n = 8) measured over 1.5 years
Variable v1 v2
sCysC (mg/L) 1.42 × 10-4 2.78 × 10-4
uRBP/c (mg/g) 9.25 × 10-4 1.04 × 10-3
uNGAL/c (μg/g) 4.11 3.96
uIgG/c (mg/g) 120.6 242.9
sCysC, serum cystatin C; uRBP/c, urinary RBP-to-creatinine ratio; uNGAL/
c, urinary NGAL-to-creatinine ratio; uIgG/c, urinary IgG-to-creatinine ratio.
TABLE 2 Mean  within-dog SD and within- and between-dog 95%
reference intervals and CV for within-dog repeated measures of
sCysC, uRBP/c, uNGAL/c and uIgG/c in healthy beagles (n = 8)
measured over 1.5 years
Variables Mean  SD
Within-dog
95%
reference
interval
Between-dog
95%
reference
interval CV
sCysC (mg/L) 0.15  0.01 0.12 - 0.17 0.11 - 0.19 8.1%
uRBP/c (mg/g) 0.09  0.03 0.03 - 0.15 0.00 - 0.18 33.7%
uNGAL/c (μg/g) 2.32  2.03 0.00 - 6.3 0.00 - 7.89 87.2%
uIgG/c (mg/g) 12.47  10.98 0.00 - 33.99 0.00 - 49.83 88.1%
SD, within-dog standard deviation; CV, coefficient of variation; sCysC,
serum cystatin C; uRBP/c, uRBP-to-creatinine ratio; uNGAL/c,
uNGAL-to-creatinine ratio; uIgG/c, uIgG-to-creatinine ratio.
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compare different studies and to establish generally applicable refer-
ence intervals that reflect exact sCysC concentrations.7
Long-term variability of uCRP, uRBP, uNGAL and uIgG has not
been previously assessed in dogs or in other companion animal spe-
cies. Even in humans, data are scarce. Thus, this study is the first to
demonstrate high variability over time of markers of kidney disease
uRBP, uNGAL and uIgG. Yet, of the urinary markers evaluated,
uRBP/c seems least prone to within-dog variability. RBP, a 21 kDa
plasma protein, is freely filtered through the glomerulus in the
unbound form, and in healthy animals mostly reabsorbed and catabo-
lized in the proximal tubules.23 The presence of RBP in urine occurs
when tubules are injured, when abnormal amounts of proteins com-
pete for reabsorption, or both.10 An undetectable to a low uRPB/c of
<0.15 mg/g is expected in healthy dogs.10 The overall mean  within-
dog SD from the current study (0.09  0.01 mg/g) corroborates this
finding and only one dog had a concentration below the LOD. Day-to-
day CV of 9.2 to 10.5% occurs in humans.24 The within-dog CV of the
current study is much higher, possibly as a result of the longitudinal
nature of the study. Nevertheless, the variation is still moderate com-
pared to that of uIgG/c and uNGAL/c. Therefore, uRBP/c might still
be potentially useful as urinary markers reflect lesions and physiology
occurring in the kidneys more directly and might be a more sensitive
indicator of injury than their systemic counterparts.25,26 Since there
are contradicting studies on whether uRBP/c can detect renal dys-
function at an early stage,12,27,28 additional studies are needed to
determine the usefulness of this marker in the diagnosis of early CKD.
Both uNGAL/c and uIgG/c demonstrated high within-dog CVs.
The high variability in normal dogs implies that to be a good clinical
marker (i.e., to allow an accurate discrimination of health status), the
difference between healthy and diseased dogs (e.g., CKD) needs to be
bigger relative to markers with a small CV. NGAL is similar to RBP as a
low MW protein marker of kidney disease but can also be synthesized
by damaged tubular epithelial cells.10 uNGAL/c is <6 μg/g in healthy
dogs, which corroborates with the current study’s overall mean.10
Only one dog had an uNGAL concentration below the LOD. Within-
dog CV of this longitudinal study also corroborates with high day-to-
day biological variation of uNGAL/c in humans (CV ranging from 75%
to 101%).29–31 Variation from samples collected repeatedly within the
same day is higher than between days.32 The reason for this high vari-
ation is currently unknown. It should be highlighted that urinary levels
in healthy dogs were 1000-fold lower than for the other two markers,
uRBP and uIgG. To that extent, uNGAL/c might still have potential to
detect early CKD, provided that the rise in concentration is high
enough despite the high variation in healthy dogs. However, its ability
to diagnose early CKD is still requires investigation as during early
stages of canine X-linked hereditary nephropathy, when GFR is
decreasing from >3.5 to 1.5-2.5 mL/min/kg, uNGAL/c increases
2-fold and then plateaus as GFR continues to decrease.12
Immunoglobulin G is a high MW protein (150 kDa) that plays a
part in the humoral immune system.23 uIgG/c is increased in dogs with
CKD and is positively correlated to glomerular lesions.12,13 Moreover,
it is increased in early stages of CKD related to X-linked hereditary
nephropathy in dogs.12 The overall mean of uIgG/c from the current
study was slightly higher than the observed maximum of 10 mg/g
from healthy dogs in other studies.10 Factors that affect uIgG
concentrations in healthy dogs are still undetermined. Moreover, bio-
logical variation of uIgG/c in either humans or in other companion ani-
mal species than dogs has not been investigated. One possible
explanation for the variation is that uIgG/c is significantly correlated
to UPC.12 In our study, a dog with mild proteinuria after the start of
the study but was otherwise healthy had higher but relatively stable
uIgG/c compared to other dogs. Despite the proteinuria, we chose to
keep the dog in the study. Other than an increase in UPC between
week 0 and week 12 (i.e., from 0.25 to 0.72), it fluctuated between
0.42 and 0.80 in the current study. According to Nabity and col-
leagues, for UPC values near 0.5, UPC must change by at least 80%
before a change can be considered significant and warrant further
investigation.33 For UPC values starting at <0.2 or borderline protein-
uria, as with the dog in our study, guidelines have not been proposed
nor investigated. Moreover, this study was based on dogs with glo-
merular proteinuria caused by X-linked hereditary nephropathy, and
whether this guideline can be applied to other glomerular diseases is
still unknown.33 Although this dog’s proteinuria could be age-related
as this dog was eight years at the start of the study, data linking pro-
teinuria to aging in dogs is limited.34 Future studies need to determine
the age effect, as well as other factors on uIgG/c.
In accordance with the majority of other studies of markers of
kidney disease in dogs that included a healthy control group, dogs in
our study also had uCRP concentrations below the detection
limit.11,17,18,35–39 CRP is a major positive acute phase protein in dogs
with a large MW (110 to 144 kDa) and therefore is unable to pass
through an intact glomerular barrier, which probably was the case in
the healthy dogs in our study.10 Further investigation into uCRP as a
marker to detect the presence of glomerular injury is still warranted.
Although hematuria could potentially interfere with accurate
determination of urinary analyte concentrations, its influence on
uRBP/c, uIgG/c and uCRP/c seems to be limited.35,40 Furthermore, in
the current study, hematuria was microscopic, most likely due to con-
tamination from the cystocentesis, and only present in a small portion
of the samples. Hence, the effect of hematuria on our results was
negligible.
Because the dogs used in our study were from the same breed,
kept in the same environment and were fed the same diet, the results
of the current study cannot be applied to the general population of
dogs. Therefore, studies in a large mix-breed population are required.
In such studies, the contribution of breed, sexual status, and age to
the variation of biomarkers can also be assessed as to determine
whether separate reference ranges are necessary. Furthermore, it
would be interesting to determine, especially for the biomarkers with
low within-dog variation, the change in concentration needed before
it can be considered as indicative of disease.
In conclusion, markers of kidney disease sCysC, uRBP/c,
uNGAL/c and uIgG/c show a wide range of intra-individual variation
in healthy dogs, which might affect their interpretation. sCysC had the
lowest variation, while the other markers exhibited large variation.
Clinically, if there is only a slight difference in concentration between
healthy dogs and dogs with CKD, a value indicative of disease will
likely be difficult to detect with the latter three markers, while the for-
mer might still be able to discriminate between dogs with or without
renal damage. In other words, to be of added diagnostic value, the
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difference between healthy dogs and dogs with CKD would have to
be considerable for uRBP/c, uNGAL/c and uIgG/c. While this study
provides important information on the long-term variability of markers
of kidney disease in healthy dogs, future studies have to assess
whether there is an overlap of concentrations between healthy dogs
and dogs with CKD.
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